ORYZON Genomics
Calle Sant Ferran 74
Cornella de Llobregat
Barcelona
08940
Tel: 34-93-5151313
Fax: 34-93-3774028
Website: http://www.oryzon.com/
Email: info@oryzon.com
130 articles with ORYZON Genomics
-
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients
3/15/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase mutation (FLT3mut+), at the Massachusetts General Hospital in Boston, US.
-
ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
2/22/2023
Oryzon Genomics, S.A. announced that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici, Dr. med. Peter Hahn, and Dr. Olga Salamero, discussing the unmet medical needs in specific central nervous system and oncology diseases.
-
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
2/17/2023
Oryzon Genomics, S.A. reported financial results for the fourth quarter ended December 31, 2022 and provided an update on recent developments.
-
ORYZON to Give Updates on Corporate Progress in February-March
2/6/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events on February-March.
-
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
1/18/2023
Oryzon Genomics, S.A. announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).
-
ORYZON to Give Updates on Corporate Progress in January 2023
1/5/2023
Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in January.
-
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
12/16/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV-K Vaccination and Epigenetic modulation) under the Eurostars-3 program.
-
ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022
12/12/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 64th American Society of Hematology (ASH) Annual Conference.
-
ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)
11/9/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).
-
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022CNS
11/2/2022
Oryzon Genomics, S.A. reported financial results for the third quarter of 2022 and provided an update on recent developments.
-
ORYZON to Give Updates on Corporate Progress in October
10/3/2022
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in October.
-
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
9/16/2022
Oryzon Genomics, S.A. today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communication at the 10th European Conference on Mental Health (ECMH), being held in Lisbon (Portugal) on September 13-16.
-
ORYZON to Give Updates on Corporate Progress in September 2022
9/8/2022
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in September.
-
ORYZON Collaborates with the CMT Research Foundation in the US
7/26/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors.
-
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
7/22/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2022 and provided an update on recent developments.
-
Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.
-
ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers
7/19/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
-
Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.
-
ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €20 Million Over 30 Months
7/5/2022
Oryzon Genomics, S.A. announced today the entry into a convertible bonds financing agreement (the “Issuance Agreement”) with Nice & Green in bonds convertible into new shares for a total amount of €20 Million.
-
ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML
6/10/2022
Oryzon Genomics, S.A. today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML).